<DOC>
	<DOC>NCT00506792</DOC>
	<brief_summary>This study will investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic response of patients with cystic fibrosis to administration of QAU145 via intranasal spray.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male and female (women must be postmenopausal or surgically sterile) subjects with cystic fibrosis ages 18 to 50. Any presence of seasonal or nonseasonal allergies affecting the nose, nasal passages, throat or sinuses within 2 weeks prior to dosing. Any upper respiratory tract infection or signs or symptoms within 2 weeks prior to dosing. Any presence of nasal polyps or structural abnormalities, frequent history of nose bleeding, or any recent nasal surgery (within 12 weeks prior to dosing).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Cystic fibrosis, QAU145, nasal potential difference</keyword>
</DOC>